In comparison to patients with homozygous mutations, individuals exhibiting symptomatic heterozygous variations in the HTRA1 gene typically experience a delayed onset of strokes, disturbances in gait, and cognitive deterioration, while notably lacking the characteristic extracerebral symptoms that are typically associated with CARASIL.[6]. This evidence concerns the gene HTRA1 and stroke disorder.